Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Treasury Shares (2016 - 2025)

Fortress Biotech has reported Treasury Shares over the past 13 years, most recently at $3.8 million for Q4 2025.

  • Quarterly results put Treasury Shares at $3.8 million for Q4 2025, down 12.98% from a year ago — trailing twelve months through Dec 2025 was $3.8 million (down 12.98% YoY), and the annual figure for FY2025 was $3.8 million, down 12.98%.
  • Treasury Shares for Q1 2020 was $70000.0 at Fortress Biotech.
  • Over the last five years, Treasury Shares for FBIO hit a ceiling of $23.0 million in Q1 2023 and a floor of $1.4 million in Q4 2022.
  • Median Treasury Shares over the past 5 years was $5.6 million (2025), compared with a mean of $10.7 million.
  • Biggest five-year swings in Treasury Shares: soared 368650.26% in 2021 and later crashed 92.83% in 2023.
  • Fortress Biotech's Treasury Shares stood at $18.1 million in 2021, then tumbled by 92.41% to $1.4 million in 2022, then skyrocketed by 50.86% to $2.1 million in 2023, then surged by 113.6% to $4.4 million in 2024, then fell by 12.98% to $3.8 million in 2025.
  • The last three reported values for Treasury Shares were $3.8 million (Q4 2025), $5.1 million (Q3 2025), and $5.7 million (Q2 2025) per Business Quant data.